Sage Therapeutics Reports Phase 2 Huntington's Data

Sage Therapeutics, Inc. SAGE shares are trading lower on Tuesday. The company eelier announced results from its Phase 2 Huntington’s Disease clinical study.

The Details: On Tuesday before the market opened, Sage Therapeutics announced topline results from its Phase 2 SURVEYOR Study, which met its primary endpoint demonstrating a statistically significant difference as measured by the HD-CAB composite score at baseline.

The study contained three different goals: assess the level of cognitive impairment in HD patients compared to healthy individuals, evaluate the safety of dalzanemdor in HD participants and understand how changes in cognition relate to changes in function.

Dalzanemdor was generally well tolerated with no new safety signals observed.

Sage Therapeutics expects to report topline data from two studies, the LIGHTWAVE Study and the DIMENSION Study, in late 2024.

Analyst Changes: Separately, two analysts issued price target adjustments.

• Baird analyst Joel Beatty maintained a Neutral rating and $15 price target.
• Needham analyst Ami Fadia reiterated coverage with a Hold.

See Also: Top 4 Health Care Stocks That May Keep You Up At Night This Month

SAGE Price Action: Sage Therapeutics shares were trading 5.78% lower at $10.27 at the time of publication, according to Benzinga Pro.

Image: Photo via Shutterstock